Details for Patent: 7,491,725

Which drugs does patent 7,491,725 protect, and when does it expire?

Patent 7,491,725 protects SPRYCEL and is included in one NDA.

Protection for SPRYCEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in twenty-nine countries.

Summary for Patent: 7,491,725

Title:	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Abstract:	The invention relates to processes for preparing compounds having the formula, ##STR00001## and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R.sub.2, R.sub.3, R.sub.4, and R.sub.5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
Inventor(s):	Lajeunesse; Jean (Candiac, CA), DiMarco; John D. (East Brunswick, NJ), Galella; Michael (Kendall Park, NJ), Chidambaram; Ramakrishnan (Pennington, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	11/192,867
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,491,725
Patent Claim Types: see list of patent claims	Compound; Composition; Process;

Drugs Protected by US Patent 7,491,725

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-001	Jun 28, 2006		RX	Yes	No					Y
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-002	Jun 28, 2006		RX	Yes	No					Y
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-003	Jun 28, 2006		RX	Yes	No					Y

International Family Members for US Patent 7,491,725

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047533
Argentina	053984
Austria	E453630